Watch XERS. Know when insiders buy.
One email the day a filing lands. Free.
XERS
Xeris Biopharma Holdings, Inc.
10.79
−0.34 −3.05%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
49
WATCH · insiders 26, shorts 71
Insiders, 90 days
−$906K
net selling · 0 buys, 7 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $2BP/E —DIV YIELD —FCF YIELD —REV TTM $335.4M +36.3%NET INCOME −$17.2MNET DEBT $130.8M52W 5.29 – 11.13NEXT EARNINGS Nov 5SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $92.1M | +28.7% | — | $5.2M | −$31.1M | — | -0.18 | $8.3M | — | — | Aug 6 |
| Q1 2026 · Mar 31 | $83.1M | +38.3% | — | $7.9M | $2.2M | — | 0.01 | $9.9M | — | — | Aug 6 |
| Q4 2025 · Dec 31derived | $85.8M | +42.8% | — | $16.8M | $11.1M | — | 0.07 | $20M | — | — | Mar 2 |
| Q3 2025 · Sep 30 | $74.4M | +37.1% | — | $6.7M | $621K | — | 0.00 | $18.4M | — | — | Nov 6 |
| Q2 2025 · Jun 30 | $71.5M | +48.8% | — | $4.5M | −$1.9M | — | -0.01 | $182K | — | — | Aug 6 |
| Q1 2025 · Mar 31 | $60.1M | +47.9% | — | −$3.1M | −$9.2M | — | -0.06 | −$10M | — | — | Aug 6 |
| Q4 2024 · Dec 31derived | $60.1M | +35.4% | — | $1.7M | −$5.1M | — | -0.03 | $2M | — | — | Mar 2 |
| Q3 2024 · Sep 30 | $54.3M | +12.3% | — | −$12.9M | −$15.7M | — | -0.11 | −$8.3M | — | — | Nov 6 |
| Q2 2024 · Jun 30 | $48.1M | — | — | −$8.2M | −$15M | — | -0.10 | −$10.3M | — | — | Nov 6 |
| Q1 2024 · Mar 31 | $40.6M | — | — | −$14.2M | −$19M | — | -0.14 | −$20.3M | — | — | Nov 6 |
| Q4 2023 · Dec 31derived | $44.4M | — | — | −$9.8M | −$13.4M | — | -0.09 | $7.5M | — | — | Mar 2 |
| Q3 2023 · Sep 30 | $48.3M | — | — | −$4.9M | −$12.2M | — | -0.09 | −$14.6M | — | — | Nov 8 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $291.8M | — | $24.9M | $554K | 0.2% | 0.00 | $28.6M | — | — | — | — |
| FY2024 · to Dec 31 | $203.1M | — | −$33.6M | −$54.8M | -27.0% | -0.37 | −$37M | — | — | — | — |
| FY2023 · to Dec 31 | $163.9M | — | −$44M | −$62.3M | -38.0% | -0.45 | −$47M | — | — | — | — |
| FY2022 · to Dec 31 | $110.2M | — | −$81.9M | −$94.7M | -85.9% | -0.70 | −$102.9M | — | — | — | — |
| FY2021 · to Dec 31 | $49.6M | — | −$115.2M | −$122.7M | -247.5% | -1.55 | −$95.5M | $1.1M | −$96.6M | — | — |
| FY2020 · to Dec 31 | $20.4M | — | −$83.5M | −$91.1M | -446.0% | -2.14 | −$80.6M | $377K | −$80.9M | — | — |
Every number comes from Xeris Biopharma Holdings, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.